Bio Rad Valuation
| BIO Stock | USD 277.36 2.79 1.00% |
At this time, the firm appears to be undervalued. Bio Rad Laboratories shows a prevailing Real Value of $325.92 per share. The current price of the firm is $277.36. Our model approximates the value of Bio Rad Laboratories from analyzing the firm fundamentals such as Current Valuation of 7.72 B, profit margin of (0.72) %, and Return On Equity of -0.24 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bio Rad's valuation include:
Price Book 1.1942 | Enterprise Value | Enterprise Value Ebitda (13.07) | Price Sales 3.1208 | Forward PE 30.4878 |
Undervalued
Today
Please note that Bio Rad's price fluctuation is very steady at this time. Calculation of the real value of Bio Rad Laboratories is based on 3 months time horizon. Increasing Bio Rad's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bio Rad is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Rad's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 277.36 | Real 325.92 | Target 404.33 | Hype 270.6 | Naive 265.39 |
The intrinsic value of Bio Rad's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bio Rad's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bio Rad Laboratories helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Rad more accurately as focusing exclusively on Bio Rad's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bio Rad's intrinsic value based on its ongoing forecasts of Bio Rad's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bio Rad's closest peers.
Bio Rad Cash |
|
Bio Valuation Trend
Knowing Bio Rad's actual value is paramount for traders when making sound investment determinations. Using both Bio Rad's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Bio Revenue by Product
Bio Rad Total Value Analysis
Bio Rad Laboratories is currently forecasted to have company total value of 7.72 B with market capitalization of 8.01 B, debt of 174.3 M, and cash on hands of 434.21 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Bio Rad fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.72 B | 8.01 B | 174.3 M | 434.21 M |
Bio Rad Investor Information
About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.19. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio Rad Laboratories has Price/Earnings To Growth (PEG) ratio of 1.19. The entity recorded a loss per share of 65.37. The firm had not issued any dividends in recent years. Bio Rad had 2:1 split on the 8th of March 2002. Based on the measurements of operating efficiency obtained from Bio Rad's historical financial statements, Bio Rad Laboratories is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 478 M | 455.2 M |
|
|
Bio Rad Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bio Rad has an asset utilization ratio of 27.41 percent. This suggests that the Company is making $0.27 for each dollar of assets. An increasing asset utilization means that Bio Rad Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.Bio Rad Ownership Allocation
Bio Rad holds a total of 22.94 Million outstanding shares. The majority of Bio Rad Laboratories outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Rad Laboratories to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Rad. Please pay attention to any change in the institutional holdings of Bio Rad Laboratories as this could imply that something significant has changed or is about to change at the company. Also note that nearly thirty-two thousand one hundred seventeen invesors are currently shorting Bio Rad expressing very little confidence in its future performance.Bio Rad Profitability Analysis
The company reported the last year's revenue of 2.57 B. Reported Net Loss for the year was (99.4 M) with profit before taxes, overhead, and interest of 1.38 B.About Bio Rad Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Bio Rad Laboratories. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bio Rad Laboratories based exclusively on its fundamental and basic technical indicators. By analyzing Bio Rad's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Bio Rad's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bio Rad. We calculate exposure to Bio Rad's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bio Rad's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.4 B | 787.9 M | |
| Pretax Profit Margin | (0.91) | (0.87) | |
| Operating Profit Margin | 0.10 | 0.08 | |
| Net Loss | (0.72) | (0.68) | |
| Gross Profit Margin | 0.54 | 0.63 |
Bio Rad Quarterly Retained Earnings |
|
Bio Rad Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 28.2 M | |
| Quarterly Earnings Growth Y O Y | 5.412 | |
| Forward Price Earnings | 30.4878 |
Bio Rad Current Valuation Indicators
Bio Rad's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Bio Rad's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bio Rad, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bio Rad's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bio Rad's worth.When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (65.37) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.